Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
F1000Res ; 12: 358, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37767018

RESUMO

Introduction: Coronavirus disease 2019 (COVID-19) cases caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Indonesia remain high. The virus can bind with ACE2 receptor which is not only found in the lungs, but also in the digestive tract. Thus, it allows SARS-CoV-2 infection in the gastrointestinal tract, gastrointestinal manifestations, and detection of viral RNA on anal swab using polymerase chain reaction (PCR). There hasn't been similar study about the role of anal swab in Indonesia yet. Therefore, this study aims to determine the relationship between SARS-COV-2 anal swab PCR with gastrointestinal clinical manifestations, and the severity of COVID-19 in Indonesia. Methods: This is an analytical study with cross-sectional design. Samples were obtained from hospitalized COVID-19 patients from July 2020 to January 2021. Demographic data, clinical manifestations, severity, and SARS-CoV-2 anal swabs PCR were collected using case report form. Results: A total of136 patients were analyzed. 52 patients (38.2%) had positive SARS-CoV-2 anal swabs PCR and 84 patients (61.8%) had negative results. The most common gastrointestinal clinical manifestations were nausea and vomiting in 69 patients (50.7%), anorexia in 62 patients (45.6%), and abdominal pain in 31 patients (22.8%). There were 114 patients (83,8%) classified as mild-moderate symptoms and 22 patients (16,2%) classified as severe-critical symptoms. There was a statistically significant relationship between the gastrointestinal tract SARS-CoV-2 infection and gastrointestinal clinical manifestations (P=0.031). There was no statistically significant relationship between the gastrointestinal SARS-CoV-2 infection and the severity of COVID-19 infection (P = 0.844). Conclusions: This study showed there is a significant relationship between SARS-CoV-2 anal swab PCR with gastrointestinal clinical manifestations. There is no significant relationship between anal swab PCR with the severity of COVID-19 infection.


Assuntos
COVID-19 , SARS-CoV-2 , Humanos , SARS-CoV-2/genética , COVID-19/diagnóstico , Estudos Transversais , Indonésia/epidemiologia , Trato Gastrointestinal , Reação em Cadeia da Polimerase , Teste para COVID-19
2.
Gut Pathog ; 15(1): 25, 2023 May 22.
Artigo em Inglês | MEDLINE | ID: mdl-37217981

RESUMO

Dyspepsia still becomes a major challenge in upper gastrointestinal disease in Indonesia. This disease often correlated with Helicobacter pylori infection. However, the prevalence of this bacterium is generally low in Indonesia. Therefore, several considerations should be taken into consideration during the management of dyspepsia and H. pylori infection. "Management of dyspepsia and H. pylori infection in Indonesia: The Indonesian consensus report" comprises information gathered from 22 gastroenterology centers across Indonesia. The experts gathered to evolve a consensus, that consists of the statements, grades of recommendations, evidence levels, and rationales for the dyspepsia and H. pylori infection management for daily clinical practice. The report explains several aspects from the updated epidemiology information to comprehensive management therapy. After the experts worked together on all statements in the recommendations, the results are presented with the final agreement as a consensus to help clinicians in understanding, diagnosing, and treating dyspepsia and H. pylori infection patients in daily clinical practice in Indonesia.

3.
Acta Med Indones ; 55(1): 33-39, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-36999263

RESUMO

BACKGROUND: Inflammation in chronic functional constipation (CFC) occurs systemically and has association with depressive symptoms. Biomarkers of inflammation can be assessed by the neutrophil to lymphocyte ratio and platelet to lymphocyte ratio. These inflammation biomarkers are stable, cheap, and widely available. This study aimed to determine the profile and the correlations between depressive symptoms and inflammation in CFC patients. METHODS: This cross-sectional study involved subjects aged 18-59 years with chronic functional constipation. We use validated Beck Depression Inventory-II (BDI-II) to assess depressive symptoms. We collected the data regarding complete peripheral blood examination, liver function, kidney function, electrolytes, and neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR). Bivariate analysis with Chi-Square test for categorical data and t-test or ANOVA test for numerical data. Multivariate analysis used logistic regression to look at risk factors for depression with p < 0.05 as a statistical significant level. RESULTS: A total of 73 subjects with CFC were recruited with a mean age is 40.2 years, mostly women and working as housewives. Proportion of depressive symptoms in CFC patients was 73.0%, including mild depression 16.4%, moderate depression 17.8%, and severe depression (28.8%). The mean NLR in non-depressive subjects was 1.8 (SD 0.7), while in depressive subjects was 1.94 (SD 0.1) (p>0.05). The mean NLR in mild depression subjects was 2.2 (SD 1.7), in moderate depression was 2.0 (SD 0.7), and in severe depression was 1.9 (SD 0.5) (p>0.05). The mean PLR in non-depressive subjects was 134.3 (SD 0.1), whereas in depressive subjects it was 138.9 (SD 46.0) (p>0.05). The mean PLR in mild depression subjects was 142.9 (SD 60.6), in moderate depression was 135.4 (SD 41.2), and in major depression was 139.0 (SD 37.1) (p>0.05). CONCLUSION: This study found that CFC patients were middle-aged, mostly women and working as a housewife. In general, biomarkers of inflammation were found to be higher in depressive subjects than non-depressive subjects, although not statistically significant.


Assuntos
Depressão , Linfócitos , Pessoa de Meia-Idade , Humanos , Feminino , Adulto , Masculino , Contagem de Linfócitos , Estudos Transversais , Neutrófilos , Biomarcadores , Inflamação , Constipação Intestinal , Estudos Retrospectivos
5.
PLoS One ; 16(12): e0250234, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34914726

RESUMO

AIM: To investigate the effect of influenza vaccination with or without probiotic supplementation on the immune response and incidence of influenza-like illness (ILI) in the elderly. METHODS: A randomized double-blind, placebo-controlled trial with a modified factorial design was conducted in 554 healthy elderly subjects aged 67 ± 5.6 (ranging from 60-90) years old in the Primary Health Care Center (Puskesmas area) of the Pulo Gadung District East Jakarta. Subjects received either a trivalent influenza vaccine or placebo at the start of the study, and a probiotic supplement (Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011) or a placebo for 6 months. Subjects were randomly assigned into four intervention groups: influenza vaccine and probiotics (n = 141), influenza vaccine and placebo (n = 136), placebo and probiotics (n = 140), and both placebo (n = 137). The primary outcome was ILI incidence within 6 months. The secondary outcomes were seroprotection and seroconversion rates at 1, 4, and 6 months after administering the interventions. RESULTS: This study showed that the trivalent influenza vaccine increased seroprotection (RR 3.6 [95%CI 2.92-4.47]; p<0.010) and seroconversion (RR 29.8 [95%CI 11.1-79.5]; p<0.010) rates 1 month after vaccination in elderly people while the probiotic supplement did not alter influenza antibody titers (p = 1.000 and p = 0.210). The relative ILI incidence risk was similar between vaccinated and non-vaccinated groups, as well as in the probiotic group compared to the non-probiotic group. CONCLUSION: The tested trivalent influenza vaccine significantly induced seroprotection and seroconversion in the vaccinated subjects, while probiotics administration did not influence these parameters. Vaccinated individuals displayed a similarly low ILI incidence as those in the Control Group. However, the observed trend towards a reduction of ILI incidence with probiotics supplementation warrants further assessments in a larger, at-risk population. CLINICAL TRIAL REGISTRY NUMBER: NCT03695432.


Assuntos
Vacinas contra Influenza/administração & dosagem , Influenza Humana , Lacticaseibacillus rhamnosus , Lactobacillus helveticus , Probióticos/administração & dosagem , Idoso , Idoso de 80 Anos ou mais , Método Duplo-Cego , Feminino , Humanos , Incidência , Indonésia/epidemiologia , Influenza Humana/epidemiologia , Influenza Humana/prevenção & controle , Masculino , Pessoa de Meia-Idade
6.
Digestion ; 102(6): 823-832, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34433172

RESUMO

BACKGROUND: Researchers believe the role of gut microbiota dysbiosis in the raised incidence of early-onset colorectal cancer (EOCRC). The development of EOCRC may be associated with microbiota dysbiosis either dependently or independently (combined with other risk factors). SUMMARY: Recently, the rising of incidence and mortality of EOCRC have been noted. Some researchers are looking for risk factors influencing this fact. They hypothesize that it may be because of microbiota dysbiosis. Microbiota dysbiosis has been known to promote cancer development through immunity dysregulation and chronic inflammation. Microbiomes profile in late-onset colorectal cancer (LOCRC) among older patients has been documented, but there is still lack of data about microbial profiles among younger colorectal cancer (CRC) patients. This review tries to explain microbial profiles differences between EOCRC and LOCRC as a potential diagnostic biomarker in the future, and whether microbiota can have a role in EOCRC genesis. Key Messages: Microbiota does vary with age, and EOCRC may be associated with colonization of some specific bacteria. Further studies about gut microbiota profiles in EOCRC and LOCRC may provide a new insight on diagnostic biomarker of CRC.


Assuntos
Neoplasias Colorretais , Microbioma Gastrointestinal , Biomarcadores , Neoplasias Colorretais/diagnóstico , Neoplasias Colorretais/epidemiologia , Disbiose , Humanos , Incidência
7.
Artigo em Inglês | MEDLINE | ID: mdl-34011623

RESUMO

OBJECTIVE: This study will test the performance of the anal swab PCR test when compared with the nasopharyngeal swab PCR test as a diagnostic tool for COVID-19. DESIGN: An observational descriptive study which included hospitalised suspected, or probable cases of hopitalised COVID-19 patients, conducted in Dr. Cipto Mangunkusumo National Hospital, Ciputra Hospital, Mitra Keluarga Depok Hospital and Mitra Keluarga Kelapa Gading Hospital, Indonesia. Epidemiological, clinical, laboratory and radiology data were obtained. Nasopharyngeal and anal swabs specimens were collected for SARS-CoV-2 RNA detection. RESULTS: We analysed 136 subjects as part of this study. The clinical spectrum of COVID-19 manifesation in this study was typical of hospitalised patients, with 25% classified as mild cases, 14.7% in severe condition and 12.5% of subjects classified as having acute respiratory distress syndrome. When compared with nasopharyngeal swab as the standard specimen for reverse transcription polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 antigen, the sensitivity and specificity of the anal swab was 36.7% and 93.8%, respectively. The positive and negative predictive value were 97.8% and 16.5 %, respectively. The performance of the anal swab remained similar when only the subgroup of patients with gastrointestinal symptoms (n=92, 67.6%) was analysed (sensitivity 40% and specificity 91.7%). Out of all the subjects included in analysis, 67.6% had gastrointestinal symptoms. Similarly, 73.3% of patients in the anal swab-positive group had gastrointestinal symptoms. The two most common gastrointestinal symptoms in the subjects' population were nausea and anorexia. CONCLUSION: Anal swab specimen has low sensitivity (36.7%) but high specificity (93.8%) for detecting SARS-CoV-2 antigen by RT-PCR. Only one additional positive result was found by anal swab among the nasopharyngeal swab-negative group. Anal swab may not be needed as an additional test at the beginning of a patient's diagnostic investigation and nasopharyngeal swab RT-PCR remains as the standard diagnostic test for COVID-19.


Assuntos
Canal Anal/virologia , COVID-19/diagnóstico , Gastroenteropatias/virologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , SARS-CoV-2/genética , Adulto , COVID-19/epidemiologia , COVID-19/virologia , Teste para COVID-19/métodos , Testes Diagnósticos de Rotina/normas , Testes Diagnósticos de Rotina/estatística & dados numéricos , Feminino , Gastroenteropatias/diagnóstico , Hospitalização , Humanos , Indonésia/epidemiologia , Masculino , Pessoa de Meia-Idade , Nasofaringe/virologia , Valor Preditivo dos Testes , Reação em Cadeia da Polimerase Via Transcriptase Reversa/estatística & dados numéricos , Sensibilidade e Especificidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA